39 institutions hold shares in Nuvation Bio Inc. (NUVB), with 60.26M shares held by insiders accounting for 27.69% while institutional investors hold 33.99% of the company’s shares. The shares outstanding are 412.96M, and float is at 13.95M with Short Float at 9.51%. Institutions hold 24.58% of the Float.
Nuvation Bio Inc. (NYSE: NUVB) is -7.26% lower on its value in year-to-date trading and has touched a low of $8.56 and a high of $15.07 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The NUVB stock was last observed hovering at around $10.20 in the last trading session, with the day’s gains setting it 0.65% off its average median price target of $18.50 for the next 12 months. It is also 45.75% off the consensus price target high of $20.00 offered by 5 analysts, but current levels are 32.19% higher than the price target low of $16.00 for the same period.
Currently trading at $10.85, the stock is -12.28% and -2.94% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.25 million and changing 6.37% at the moment leaves the stock 0.59% off its SMA200. NUVB registered a loss of -2.30% in past 6-months. The firm has a 50-day simple moving average (SMA 50) of $11.56 and a 200-day simple moving average (SMA200) of $10.81.
The stock witnessed a 3.33% gain in the last 1 month and extending the period to 3 months gives it a -7.26%, and is 5.54% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.78% over the week and 7.45% over the month.
Distance from 52-week low is 26.75% and -28.03% from its 52-week high.
Nuvation Bio Inc. (NUVB) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Nuvation Bio Inc. (NUVB) is a “Buy”. 5 analysts offering their recommendations for the stock have an average rating of 1.40, where 0 rate it as a Hold and 0 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Nuvation Bio Inc. is expected to release its quarterly report on 09/01/2021 and quarterly earnings per share for the current quarter are estimated at -$0.05.
Nuvation Bio Inc. (NUVB) Insider Activity
A total of 3 insider transactions have happened at Nuvation Bio Inc. (NUVB) in the last six months, with sales accounting for 0 and purchases happening 3 times.